Association between hepatocellular carcinoma and type 2 diabetes mellitus in Italy: Potential role of insulin

Table 5 Clinical features of DM2 in HCC patients of the FU and CO groups (%)

	FU group	CO group	P
Prevalence of DM2	92 (30.2)	53 (33.1)	0.51
HbA1c (mean% ± SD)	8.2 ± 2.78	7.1 ± 2.12	0.1
Insulin therapy	45 (48.9)	15 (28.3)	0.01
Antidiabetic oral agents	47 (51.1)	38 (71.7)	0.01
Diet with/without metformin	7 (14.9)	4 (10.5)	0.55
Sulfonylureas with/without metformin	40 (85.1)	34 (89.5)	0.55
Duration of DM2 (mean ± SD, mo)	127.8 ± 80.1	167.1 ± 114.3	0.03
Duration of insulin therapy (mean ± SD, mo)	50.0 ± 50.5	77.8 ± 86.4	0.12

FU: Follow-up group; CO: Clinically overt group; HbA1c: Glycated haemoglobin.